Physician profile
Rodrigo Machado Vieira
NPI 1558807818
$16,900.85
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2020: $351 · 2021: $4,097 · 2022: $6,621 · 2023: $5,467 · 2024: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $3,500 · Travel and Lodging: $1,164 · Food and Beverage: $704 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $3,500.00 |
| Travel and Lodging | $1,163.62 |
| Food and Beverage | $704.47 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $351.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $4,973.00 | 2020-2023 | |
| Luye Pharma (USA) Ltd. | $4,968.59 | 2023 | Rykindo |
| Teva Pharmaceuticals USA, INC. | $4,309.98 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $1,960.00 | 2022 | |
| Abbvie INC. | $269.27 | 2021-2023 | Vraylar |
| Axsome Therapeutics, INC. | $125.83 | 2023-2024 | Auvelity |
| Janssen Scientific Affairs, LLC | $121.28 | 2024 | Invega Sustenna |
| Allergan, INC. | $113.18 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $59.72 | 2023-2024 | Caplyta |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodrigo Vieira listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.